Relationship between postmenopausal hormone replacement therapy and ovarian cancer [2]

Journal of the American Medical Association

Volumn 285, Issue 24, 2001, Pages 3089-3090

  Bosetti, Cristina ^a   Negri, Eva ^a   Franceschi, Silvia ^b   Trichopoulos, Dimitrios ^c   Beral, Valerie ^d   La Vecchia, Carlo ^e   Hernandez, Enrique ^f   Rodriguez, Carmen ^g   Calle, Eugenia E ^g   Jacobs, Eric J ^g   Patel, Alpa V ^g   Thun, Michael J ^g  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c HARVARD CENTER FOR CANCER PREVENTION   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g AMERICAN CANCER SOCIETY   (United States)

Author keywords

Adverse reaction; Estrogen replacement therapy; Hormone replacement therapy; Mortality; Ovarian neoplasms; Post menopausal; Risk factors; Women s health

Indexed keywords

ESTROGEN; HORMONE; ORAL CONTRACEPTIVE AGENT;

FEMALE; HORMONE SUBSTITUTION; HUMAN; MORTALITY; NOTE; OVARY TUMOR; RISK FACTOR; BONE METABOLISM; CANCER RISK; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; LETTER; MENOPAUSE; ORAL CONTRACEPTION; OVARY ADENOCARCINOMA; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; RISK;

ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OVARIAN NEOPLASMS; RISK FACTORS; CASE-CONTROL STUDIES; ODDS RATIO;

EID: 0035958345     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.24.3089     Document Type: Letter

References (0)